The University of Southampton
University of Southampton Institutional Repository

Double hit lymphoma: How do we define it and how do we treat it?

Double hit lymphoma: How do we define it and how do we treat it?
Double hit lymphoma: How do we define it and how do we treat it?

Double/triple hit lymphoma is recognised as a distinct entity within the heterogeneous group of high grade B-cell lymphomas, accounting for between 5 and 10% of cases of diffuse large B-cell lymphoma. Under the WHO 2016 it is now known as high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. When treated with standard chemotherapy it has a poor outcome. There is currently no standard of care for the management of this condition. Diagnosing double hit lymphoma requires identification of translocations of MYC and BCL2 and/or BCL6. This review will discuss the role of stratification to screen cases based on immunohistochemical profiling as a viable option. Treatment options in the frontline and relapsed setting will be reviewed based on the current literature. Recognition of the risk of CNS involvement and how best to manage this will be discussed. Future considerations and current research will be described.

BCL2, BCL6, Diffuse large B-cell lymphoma, Double-hit lymphoma, High grade lymphoma, MYC
1521-6926
Merron, Brídgín
c3520aba-2b72-44cd-8e5e-d24cf4a78632
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Merron, Brídgín
c3520aba-2b72-44cd-8e5e-d24cf4a78632
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

Merron, Brídgín and Davies, Andrew (2018) Double hit lymphoma: How do we define it and how do we treat it? Best Practice & Research: Clinical Haematology. (doi:10.1016/j.beha.2018.07.012).

Record type: Article

Abstract

Double/triple hit lymphoma is recognised as a distinct entity within the heterogeneous group of high grade B-cell lymphomas, accounting for between 5 and 10% of cases of diffuse large B-cell lymphoma. Under the WHO 2016 it is now known as high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. When treated with standard chemotherapy it has a poor outcome. There is currently no standard of care for the management of this condition. Diagnosing double hit lymphoma requires identification of translocations of MYC and BCL2 and/or BCL6. This review will discuss the role of stratification to screen cases based on immunohistochemical profiling as a viable option. Treatment options in the frontline and relapsed setting will be reviewed based on the current literature. Recognition of the risk of CNS involvement and how best to manage this will be discussed. Future considerations and current research will be described.

Full text not available from this repository.

More information

Accepted/In Press date: 20 July 2018
e-pub ahead of print date: 26 July 2018
Keywords: BCL2, BCL6, Diffuse large B-cell lymphoma, Double-hit lymphoma, High grade lymphoma, MYC

Identifiers

Local EPrints ID: 423838
URI: https://eprints.soton.ac.uk/id/eprint/423838
ISSN: 1521-6926
PURE UUID: 3c2a701b-b321-4419-a52f-3b3a34538463

Catalogue record

Date deposited: 02 Oct 2018 16:30
Last modified: 02 Oct 2018 16:30

Export record

Altmetrics

Contributors

Author: Andrew Davies

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×